Bush Tia L

CTO Bush Tia L sold 40,000 CNTA shares at $28.00 on 2025-11-17 (total $1.1M); stock now at $28.36, up 64.1% in 90 days.

Bush Tia L, Chief Technology & Quality Officer, divested 40,000 shares (24.8% of her pre-transaction holdings) at $28.00, reducing her stake from 161.5K to 121.5K shares. The sale occurred at the 52-week high of $28.36, and the stock has appreciated 64.1% over 90 days—suggesting the sell was not well-timed for capturing further gains. Her prior CNTA trades show mixed outcomes: a recent sell on 2025-11-12 is unmeasured, while three earlier 2025 sales posted modest positive returns (0.6% to 14.2% at 30 days), with none yet reaching measurable 90-day marks. Against this backdrop, Centessa remains unprofitable (net income of $-54.9M annually) with zero quarterly revenue, making fundamental execution risk material despite the stock's recent rally.

CTO Tia L. Bush sells 40,000 CNTA shares at $26.00; stock rallies 43.9% in 90 days post-sale

Bush, Chief Technology & Quality Officer, sold 40,000 shares (40.0K shares) at $26.00 on 2025-11-12 for $1,040,000.00 ($1.0M), reducing her position by -24.8% from 161,503 to 121,503 shares. The timing of this sale appears suboptimal: the stock has appreciated 43.9% over the 90-day period since the transaction and currently trades near its 52-week high of $26.70. Her prior sales at CNTA have shown mixed timing, with a 14.2% gain in the 30 days following one September trade, yet none of her prior sells at this ticker achieved positive outcomes at the 90-day measurement point. The company remains unprofitable with a net loss of $-54,891,000.00 ($-54.9M) in its most recent full fiscal year, making the subsequent equity rally difficult to attribute to operational improvements.

Chief Technology & Quality Officer Tia L Bush sells 35,000 CNTA shares at $24.00 (52-week high), reducing stake by 22.4%

Tia L Bush, Chief Technology & Quality Officer at Centessa Pharmaceuticals, sold 35,000 shares at $24.00 on 2025-09-24, reducing her holdings from 156.5K to 121.5K shares. The sale occurred at the 52-week high ($23.97), and she has initiated two prior sales at this ticker within days (2025-09-10 and 2025-09-09), suggesting a coordinated reduction sequence. Against a backdrop of an unprofitable company with -$50.3M net income in the latest quarter and -100.0% annual revenue growth, the timing and scale of this executive's stake reduction warrant investor attention. The stock's recent momentum (+41.0% over 30 days, +83.8% over 90 days) creates urgency to understand whether the sale reflects upcoming company announcements or carries other significance beyond the price levels achieved.

CTO Bush Tia L sold 49,792 shares in 2 transactions for $1,045,840 at avg $21.00; stock now $22.67, up 32.5% in 30 days

Bush Tia L, Chief Technology & Quality Officer, executed 2 separate sales totaling 49,792 shares for $1,045,840.00 at a blended average price of $21.00, reducing holdings by 29.1% from 171,295 shares to 121,503 shares. The stock has since rallied to $22.67, up 32.5% over the past 30 days and 83.1% over 90 days, placing it near its 52-week high of $22.71. Notably, this sale occurred against a backdrop of recent strong price momentum and a company with zero current-quarter revenue and a $-50,343,000 net loss in its most recent full fiscal year. The combination of a material position reduction by a senior technology officer concurrent with significant recent gains, paired with the company's unprofitable fundamentals, merits attention to whether underlying operational or strategic developments influenced the timing.